Share-Based Compensation - Additional Information (Details) $ / shares in Units, $ in Thousands		3 Months Ended			9 Months Ended		12 Months Ended
	Nov. 12, 2021 trading_day tranche $ / shares shares	Sep. 30, 2023 USD ($) shares	Dec. 31, 2022 USD ($) participant shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 shares	Nov. 06, 2020 shares	Jan. 02, 2019 shares
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares outstanding (in shares)		8,829,382	8,049,474	7,188,865	8,829,382	7,188,865	8,049,474	6,921,180
Total fair value of common shares vested | $					$ 1,616	$ 6,976
Legacy TOI Earnout Shares
Share-based Compensation Arrangement by Share-based Payment Award
Contingent consideration, liability (in shares)	12,500,000
Number of tranches | tranche	2
Earnout measurement period	2 years
Initial stock price threshold | $ / shares	$ 15.00
Earnout period	3 years
Threshold trading days | trading_day	20
Threshold trading day period | trading_day	30
Legacy TOI Earnout Shares | Derivative Instrument, Period, One
Share-based Compensation Arrangement by Share-based Payment Award
Contingent consideration, liability (in shares)	5,000,000
Stock price trigger (in dollars per share) | $ / shares	$ 12.50
Legacy TOI Earnout Shares | Derivative Instrument, Period, Two
Share-based Compensation Arrangement by Share-based Payment Award
Contingent consideration, liability (in shares)	7,500,000
DFPH Earnout Shares
Share-based Compensation Arrangement by Share-based Payment Award
Contingent consideration, liability (in shares)	575,000
Number of tranches | tranche	2
Earnout period	3 years
Escrow deposit percentage	50.00%
Stock options
Share-based Compensation Arrangement by Share-based Payment Award
Term of award					10 years
Maximum total number of common shares for which Stock options may be granted (in shares)									15,640	13,640
Number of shares outstanding (in shares)	11,850
Share options exchanged (in shares)	6,925,219
Compensation costs recognized | $		$ 2,563		$ 2,756	$ 7,823	8,837
Unrecognized compensation cost | $		$ 13,279			$ 13,279
Unrecognized compensation cost expected to be recognized over a weighted average period					2 years 6 months 21 days
Stock options | First anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award
Percentage of stock options					25.00%
Stock options | Equal monthly-basis vesting through fourth anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award
Percentage of stock options					75.00%
Stock options | 2021 Plan
Share-based Compensation Arrangement by Share-based Payment Award
Maximum total number of common shares for which Stock options may be granted (in shares)		6,782,851			6,782,851
RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Share options exchanged (in shares)	1,291,492
Compensation costs recognized | $		$ 1,188		2,356	$ 4,715	$ 5,848
Unrecognized compensation cost expected to be recognized over a weighted average period					2 years 6 months 21 days
Weighted-average grant date fair value (in dollars per share) | $ / shares					$ 0.64	$ 6.82
Unrecognized compensation expense | $		9,033			$ 9,033
Vested in period (in shares)					2,024,351
Net settled to cover the required withholding tax upon vesting					0
RSUs | First anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award
Percentage of stock options					16.67%
RSUs | Equal monthly-basis vesting through fourth anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award
Percentage of stock options					83.33%
Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares outstanding (in shares)	2,210
Medical RSUs
Share-based Compensation Arrangement by Share-based Payment Award
Compensation costs recognized | $		$ 814			$ 872
Number of shares outstanding (in shares)		0	147,470		0		147,470
Vested in period (in shares)					971,758
Award requisite service period							1 year
Shares granted, trailing closing price per share preceding grant date, period					5 days
Number of participants | participant			21
Medical RSUs, incremental share-based compensation expense | $			$ 187
Medical RSUs, after forfeitures share-based compensation expense | $			(11)
Fair value of the liability-classified medical RSU outstanding | $			$ 264				$ 264
Equity-classified medical RSUs, weighted-average grant-date fair value (in dollars per share) | $ / shares					$ 1.00		$ 3.56
Equity-classified awards outstanding (in shares)		0			0
Employees Earnout Shares
Share-based Compensation Arrangement by Share-based Payment Award
Compensation costs recognized | $		$ 92		$ 1,434	$ 319	$ 6,928
Unrecognized compensation cost expected to be recognized over a weighted average period					4 months 13 days
Number of shares outstanding (in shares)		1,401,064	1,417,632	1,437,138	1,401,064	1,437,138	1,417,632	1,602,435
Unrecognized compensation expense | $		$ 183			$ 183
Vested in period (in shares)					0	0
Employees Earnout Shares | First anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 8.35
Employees Earnout Shares | Equal monthly-basis vesting through fourth anniversary of grant date
Share-based Compensation Arrangement by Share-based Payment Award
Weighted average grant date fair value (in dollars per share) | $ / shares	$ 6.76